Special Issue

The Present and Future of Personalized Medicine in Oncology

Message from the Guest Editor

The implementation of precision medicine has tremendously increased the need for molecular characterization of tumours, as well as the amount of genetic data. Its complexity has brought to the development of so-called Molecular Tumour Boards, where clinical and genomic/transcriptomic data are discussed in order to derive relevant prognostic and predictive decisions, possibly leading to a better cancer treatment. Functional validation of a conspicuous number of molecular alterations is lacking, while it could lead to a significant rescue of patients to molecularly guided treatment. Key open questions also regard the implementation of a precision medicine approach in immunotherapy and the need for re-biopsy of progressive disease, looking for the emergence of resistance druggable mutations. This Special Issue of the *Journal of Personalized Medicine* aims to delineate present and future perspectives of precision medicine in oncology, from clinical data in real life situations to newly introduced biomarkers and emerging technologies such as liquid biopsy and patient-derived models.

Guest Editor

Dr. Federica Papaccio

Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana" , University of Salerno, 84081 Baronissi, Italy

Deadline for manuscript submissions

closed (10 October 2022)

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/si/81245

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/jpm

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/journal/jpm

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical
subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker
Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).

MDPI